News Focus
News Focus
icon url

Roman516

09/24/22 1:01 PM

#516529 RE: SkyLimit2022 #516523

SkyLimit2022, great job and supporting your comments with additional sources of information and support. Also, it is great to see H* finally open up to the fact that NWBO is on the right track. NWBO will in fact prevail based on the truth that the OS data results are real and prove effective. However, it is the testimonies of the survivors who are the real proof at hand. All who provide false information, let them stand before the cancer survivors knowing their false information holds no candle whatsoever. Yes, NWBO is moving forward in the right direction.
icon url

dr_lowenstein

09/24/22 1:12 PM

#516533 RE: SkyLimit2022 #516523

Hmmmmm he said nothing of the sort. Exemplary bullshit lol lol
icon url

exwannabe

09/24/22 1:20 PM

#516535 RE: SkyLimit2022 #516523

A crossover design was innovative?

It has been very common for these type trials long before this one started.

BTW, and exemplary design would have seen that the only approved DC vaccine had run 2 trials with PFS primary endpoint and OS secondary. Though the OS gold standard was a success, the PFS primary endpoint failed. The FDA told them to try again and they ran a trial with OS as the primary endpoint Despite crossover it worked and it was approved.